HALO
Halozyme Therapeutics, Inc.
$77.81
+0.27 (+0.35%)
At close · Jul 17
Market Cap
$9.23B
Shares
118,613,000
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-02 | 2026-06-30 | |
| 8-K | 2026-05-11 | — | |
| 10-Q | 2026-05-11 | 2026-03-31 | |
| 8-K | 2026-05-07 | 2026-05-05 | |
| 8-K | 2026-04-30 | — | |
| 8-K | 2026-04-24 | 2026-04-22 | |
| DEF 14A | 2026-03-23 | 2025-12-31 | |
| 8-K | 2026-03-12 | — | |
| 10-K | 2026-02-17 | 2025-12-31 | |
| 8-K | 2026-02-17 | — | |
| 8-K | 2026-01-28 | — | |
| 8-K | 2025-12-09 | 2025-12-04 | |
| 8-K | 2025-12-08 | 2025-12-04 | |
| 8-K | 2025-11-24 | 2025-11-18 | |
| 8-K | 2025-11-12 | 2025-11-06 | |
| 8-K | 2025-11-07 | 2025-11-06 | |
| 8-K | 2025-11-05 | — | |
| 8-K | 2025-11-03 | — | |
| 10-Q | 2025-11-03 | 2025-09-30 | |
| 8-K | 2025-10-14 | — | |
| 8-K | 2025-10-06 | 2025-10-01 | |
| 8-K | 2025-10-03 | 2025-09-30 | |
| 8-K | 2025-10-01 | 2025-09-30 | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-08-05 | — | |
| 8-K | 2025-05-06 | — | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| 8-K | 2025-05-02 | 2025-05-01 | |
| 8-K | 2025-03-21 | 2025-03-17 | |
| DEF 14A | 2025-03-18 | 2024-12-31 | |
| 8-K | 2025-02-18 | — | |
| 10-K | 2025-02-18 | 2024-12-31 | |
| 8-K | 2025-02-13 | 2025-02-11 | |
| 8-K | 2025-01-08 | — | |
| 8-K | 2024-10-31 | — | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-08-06 | — | |
| 10-Q | 2024-08-06 | 2024-06-30 | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| 8-K | 2024-05-07 | — | |
| 8-K | 2024-04-26 | 2024-04-25 | |
| DEF 14A | 2024-03-15 | 2023-12-31 | |
| 10-K | 2024-02-20 | 2023-12-31 | |
| 8-K | 2024-02-20 | — | |
| 8-K | 2024-01-17 | — | |
| 10-Q | 2023-11-06 | 2023-09-30 | |
| 8-K | 2023-11-06 | — | |
| 8-K | 2023-09-07 | 2023-09-06 | |
| 10-Q | 2023-08-08 | 2023-06-30 | |
| 8-K | 2023-08-08 | — |
Showing 1–50 of 116 filings
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
90 filings
85 filers
Visit website
Investor relations